Good find team OPT.
I've also got a Friday find for you. As you may have seen recently we've had a coverage report from Wilsons that puts us at 90c target, the kicker is that the un-risked valuation for OPT302 is $5.80 per share....
Unfortunately, to get a copy you need to chat to the Wilsons team for a copy, I cant link it here. Bottom line, the analyst Shane Storey is one of my highest top 3 rates in the biotech field - worth a read.
Cheers,
Sol
Ann: Opthea to Present at Ophthalmology Innovation Summit in US-OPT.AX, page-5
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.045(6.43%) |
Mkt cap ! $855.6M | |||
| Open | High | Low | Value | Volume |
| 69.5¢ | 69.5¢ | 63.0¢ | $2.808M | 4.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49996 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 50869 | 6 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |
